Skip to main content
Sister Publication Links
  • ESG: THE NEW IMPERATIVE
Subscribe
  • My Account
  • Login
  • Subscribe
  • News
    • Current News
    • COVID-19
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Transformation
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Digital Health
  • Insights
    • ACA 10 Years After
    • Best Practices
    • Special Reports
    • Innovations
  • Data/Lists
    • Rankings/Lists
    • Interactive Databases
    • Data Points
  • Opinion
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Custom Media Event: ESG Summit
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top 25 Innovators
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Transformation Summit
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Supply Chain Revenue Cycle
    • - Hospital at Home
    • - Workplace of the Future
    • - Virtual Health
    • - Future of Healthcare Staffing
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Video Series - The Check Up
    • Sponsored Video Series - One on One
  • MORE +
    • Advertise
    • Media Kit
    • Newsletters
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Politics & Policy
March 13, 2019 05:09 PM

Generics take the spotlight as House talks drug legislation

Susannah Luthi
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print

    House lawmakers and representatives for generic drug companies clashed Wednesday over how to handle exclusivity periods in a way that will bring more generics to market.

    Witnesses before the House Energy and Commerce Committee's health panel warned lawmakers that a proposal to potentially override existing settlements between brand and generic drug manufacturers could disrupt business, and spur lawsuits that could ultimately go against Congress' goal of bringing more generics to market.

    Rep. Nanette Diaz Barragán (D-Calif.) introduced the "Fair Act," which would allow a second generic company to share a 180-day exclusivity period for bringing the cheaper copy to market if the first generic manufacturer has entered a "pay-for-delay" agreement with the brand manufacturer. This bill would only apply to generic companies that have won a patent challenge in court or haven't been sued for a patent infringement by the competing branded drug company.

    "Adding [that] would slow things down and lead to further litigation," Kurt Karst, director of the firm Hyman, Phelps and McNamara, told lawmakers.

    Some Republican members of the committee latched onto these criticisms.

    Rep. Fred Upton (R-Mich.) said he was "particularly concerned" that existing settlements between different companies would be affected, and Rep. Morgan Griffith (R-Va.) pressed witnesses point-blank about whether the bills could make generic entry more complicated.

    Another bill, known as the "Blocking Act" also faced criticism Wednesday. The bipartisan measure by Reps. Kurt Schrader (D-Ore.) and Buddy Carter (R-Ga.) would let the Food and Drug Administration green-light a generic company's application to bring a competing drug to market if the first generic company to apply hasn't yet launched its product.

    The bill has the Trump administration's support, and the White House called for the policy in its proposed budget earlier this week.

    The House Energy and Commerce Committee's health panel was the first in both chambers of Congress to discuss legislation on drug pricing.

    Chip Davis, the CEO of the chief generics trade organization Association for Accessible Medicines (AAM) and a witness during Wednesday's hearing, opposed both the Fair Act and the Blocking Act.

    Michael Carrier, a professor with Rutgers Law School, said the legislation could prove to be "the most effective deterrent" to the type of settlements between generic and brand companies that stymie generic competition.

    The clash over how to manage exclusivity protections for early generic competition was significant since both Congress and the Trump administration view the generics market as key to lowering overall drug prices.

    The Energy and Commerce Committee, which has moved legislation at a clip this Congress, was the first in either the House or Senate to hold a hearing on specific bills for the upcoming package to address drug prices. The seven bills discussed on Wednesday are considered low-hanging fruit and included the popular bipartisan Creates Act meant to ease generics to market and longstanding "pay-for-delay" legislation.

    Additionally, the subcommittee brought up two bills to make sure manufacturers maintain up-to-date with complete patent information in FDA Orange Book and Purple Book directories.

    One bill, by Rep. Robin Kelly (D-Ill.), would require manufacturers to publish all patents related to a particular medication in the FDA's Orange Book directory. This could be significant for drugs whose high costs relate in part to patents for the devices used for application — such as insulin pens or other injectors or inhalers.

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    capitol hill
    Senate approves big Biden deal; House to vote next
    Democrats' big package: What remains in and what's out?
    Democrats' big package: What remains in and what's out?
    Sponsored Content
    Modern Healthcare Alert: Sign up for this breaking news email to be kept in the loop as urgent healthcare business news unfolds.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2022. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • COVID-19
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Digital Health
    • Insights
      • ACA 10 Years After
      • Best Practices
      • Special Reports
      • Innovations
    • Data/Lists
      • Rankings/Lists
      • Interactive Databases
      • Data Points
    • Opinion
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Excellence in Governance
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top 25 Innovators
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Conferences
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Transformation Summit
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Supply Chain Revenue Cycle
        • - Hospital at Home
        • - Workplace of the Future
        • - Virtual Health
        • - Future of Healthcare Staffing
      • Custom Media Event: ESG Summit
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Video Series - The Check Up
      • Sponsored Video Series - One on One
    • MORE +
      • Advertise
      • Media Kit
      • Newsletters
      • Jobs
      • People on the Move
      • Reprints & Licensing